CapsoVision (NASDAQ:CV) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of CapsoVision (NASDAQ:CV) to a hold rating in a research report sent to investors on Monday,Zacks reports.

Several other brokerages have also issued reports on CV. Benchmark restated a “speculative buy” rating on shares of CapsoVision in a research note on Friday, August 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. Finally, Roth Capital started coverage on CapsoVision in a research note on Friday, August 28th. They issued a “buy” rating and a $9.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.50.

CapsoVision Price Performance

Shares of CapsoVision stock opened at $5.87 on Monday. The firm has a market cap of $293.78 million, a PE ratio of -12.49 and a beta of -2.47. CapsoVision has a 1 year low of $3.43 and a 1 year high of $15.37. The stock has a fifty day moving average price of $6.55 and a 200-day moving average price of $6.42.

CapsoVision (NASDAQ:CV) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.15) earnings per share (EPS) for the quarter. The company had revenue of $3.64 million for the quarter. CapsoVision had a negative return on equity of 177.85% and a negative net margin of 214.74%. As a group, equities analysts anticipate that CapsoVision will post -0.56 EPS for the current fiscal year.

Insider Transactions at CapsoVision

In related news, major shareholder Eliyahou Et Al Harari bought 61,068 shares of the company’s stock in a transaction on Friday, July 17th. The shares were purchased at an average price of $6.73 per share, for a total transaction of $410,987.64. Following the completion of the transaction, the insider directly owned 3,343,119 shares in the company, valued at approximately $22,499,190.87. The trade was a 1.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have acquired 156,218 shares of company stock worth $1,007,902. Insiders own 2.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in shares of CapsoVision in the second quarter worth about $26,000. Deutsche Bank AG purchased a new stake in shares of CapsoVision in the fourth quarter worth $47,000. Wells Fargo & Company MN boosted its stake in CapsoVision by 66.4% during the fourth quarter. Wells Fargo & Company MN now owns 6,287 shares of the company’s stock valued at $67,000 after buying an additional 2,508 shares during the period. Virtu Financial LLC purchased a new position in CapsoVision during the fourth quarter worth about $128,000. Finally, Millennium Management LLC purchased a new stake in shares of CapsoVision in the 4th quarter valued at about $163,000.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.